Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(4-carbamimidoyl-3-chlorophenyl)-2-hydroxy-3-iodo-5-methylbenzamide is a synthetic small molecule belonging to the benzanilide class, characterized by its complex aromatic structure with halogen (chlorine and iodine) and amidine functional groups. It has been studied primarily as a research compound in medicinal chemistry for its potential to modulate or inhibit serine proteases involved in coagulation and fibrinolysis pathways, such as coagulation factor X, plasminogen, prothrombin, tissue-type plasminogen activator (tPA), trypsin, and urokinase-type plasminogen activator. Its mechanism of action is presumed to involve direct inhibition of these serine proteases through binding at their active sites. The compound’s unique structure makes it valuable for probing enzyme function and developing new anticoagulant or thrombolytic agents[6][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(4-carbamimidoyl-3-chlorophenyl)-2-hydroxy-3-iodo-5-methylbenzamide.